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Abstract
Background: KCa3.1 channels are calcium/calmodulin-regulated voltage-independent K+ channels that produce membrane
hyperpolarization and shape Ca2+-signaling and thereby physiological functions in epithelia, blood vessels, and white and
red blood cells. Up-regulation of KCa3.1 is evident in fibrotic and inflamed tissues and some tumors rendering the channel a
potential drug target. In the present study, we searched for novel potent small molecule inhibitors of KCa3.1 by testing a
series of 20 selected natural and synthetic (poly)phenols, synthetic benzoic acids, and non-steroidal anti-inflammatory drugs
(NSAIDs), with known cytoprotective, anti-inflammatory, and/or cytostatic activities.
Methodology/Principal Findings: In electrophysiological experiments, we identified the natural phenols, caffeic acid (EC50
1.3 mM) and resveratrol (EC50 10 mM) as KCa3.1 inhibitors with moderate potency. The phenols, vanillic acid, gallic acid, and
hydroxytyrosol had weak or no blocking effects. Out of the NSAIDs, flufenamic acid was moderately potent (EC50 1.6 mM),
followed by mesalamine (EC50$10 mM). The synthetic fluoro-trivanillic ester, 13b ([3,5-bis[(3-fluoro-4-hydroxy-benzoyl)ox-
ymethyl]phenyl]methyl 3-fluoro-4-hydroxy-benzoate), was identified as a potent mixed KCa2/3 channel inhibitor with an
EC50 of 19 nM for KCa3.1 and 360 pM for KCa2.3, which affected KCa1.1 and Kv channels only at micromolar
concentrations. The KCa3.1/KCa2-activator SKA-31 antagonized the 13b-blockade. In proliferation assays, 13b was not
cytotoxic and reduced proliferation of 3T3 fibroblasts as well as caffeic acid. In isometric vessel myography, 13b increased
contractions of porcine coronary arteries to serotonin and antagonized endothelium-derived hyperpolarization-mediated
vasorelaxation to pharmacological KCa3.1/KCa2.3 activation.
Conclusions/Significance: We identified the natural phenols, caffeic acid and resveratrol, the NSAID, flufenamic acid, and
the polyphenol 13b as novel KCa3.1 inhibitors. The high potency of 13b with pan-activity on KCa3.1/KCa2 channels makes
13b a new pharmacological tool to manipulate inflammation and cancer growth through KCa3.1/KCa2 blockade and a
promising template for new drug design.
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Introduction
The intermediate-conductance Ca2+-activated K+ channel,
KCa3.1, belongs to the gene family of calcium/calmodulin-
regulated and voltage-independent K+ channels (KCa2.1/2.2/2.3
and KCa3.1) [1,2] and contributes to cellular functions by
producing membrane hyperpolarization and thus regulating
intracellular Ca2+ signaling. KCa3.1 channels are expressed in
red and white blood cell lineages [3,4,5], epithelia [6,7] and
endothelia [8,9] where KCa3.1 contributes to volume regulation,
clonal expansion, fluid secretion, and vasodilatation. From the
pathophysiological perspective, up-regulation of KCa3.1 expres-
sion is a common feature of activated and proliferating cells like T-
cells [5], endothelial cells [10], neointimal smooth muscle cells
[11,12], fibroblasts [13,14], and some cancer types such as
glioblastomas [15,16,17]. In these tissues, KCa3.1 channels have
been suggested to promote immune responses [5,18], angiogenesis
[10], atherosclerosis [19], arterial restenosis [11,20], fibrosis [14],
and cancer growth [15], thus rendering the channel a promising
drug target in these disease states. Accordingly, a number of
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studies by several groups showed that small molecule inhibitors of
KCa3.1 such as TRAM-34 and ICA-17043 (Senicapoc) were to
some degree efficient in halting such disease processes in animal
models (for review see [18,21]).
Here, we screened for negative gating modulators (i.e. non-pore
inhibitors) as alternatives to the existing pore blockers [18] and
started by testing ‘‘privileged’’ drug-like structures such as simple
natural phenolic and benzoic molecules, synthetic non-steroidal
anti-inflammatory drugs (NSAIDs) and more complex synthetic
polyphenols, with reported cytoprotective, anti-inflammatory,
analgesic, and/or cytostatic activities (for structures see Figure
S1). We next tested whether the most potent novel KCa3.1-
blocking compound identified in the present study would affect
two different KCa3.1-mediated cellular functions: 1) in vitro
proliferation of fibroblasts and 2) ex-vivo endothelial vasodilator
function.
The electrophysiological screening of natural and synthetic
compounds revealed that the natural phenols, caffeic acid and
resveratrol, as well as the NSAID, flufenamic acid, are moderately
potent KCa3.1 inhibitors. The synthetic tri-fluoro trivanillic ester
([3,5-bis[(3-fluoro-4-hydroxy-benzoyl)oxymethyl]phenyl]methyl 3-
fluoro-4-hydroxy-benzoate, 13b) with a previously reported pan-
anti-kinase activity at low micromolar concentrations [22,23] was
found to be a potent KCa3.1 and KCa2.3 inhibitor with EC50s in
the lower nanomolar (KCa3.1) or picomolar range (KCa2.3) that
inhibited fibroblast proliferation and reduced endothelium-derived
hyperpolarization-mediated relaxations of porcine coronary arter-
ies.
Materials and Methods
Cell Lines
3T3 fibroblasts (3T3-L1, mouse embryonic fibroblast, ref# CL-
173, American Type Culture Collection, Rockville, MD, USA),
U251 glioblastoma cells, porcine coronary artery endothelial cells
(PCAEC), hKCa3.1-HEK293 cells [24], hKv1.2-B82 cells (murine
fibroblast cell line) [25], hKv1.3-L929 cells (fibroblast cell line
from murine lung, [26], hERG-HEK293 and hKCa2.3-COS7
cells [27] were grown in culture dishes containing Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal
calf serum (FCS) and penicillin/streptomycin (all from Biochrom
KG, Berlin, Germany). With the exception of hKCa2.3-COS7
cells, the above mentioned cell lines and cell lines stably expressing
cloned human channels were generous gifts from several sources:
The 3T3 fibroblasts were obtained from MJ Moreno-Aliaga,
Department of Physiology and Nutrition, School of Pharmacy,
University of Navarra, Pamplona, Spain. The hKCa3.1 were
obtained from Khaled Houamed, University of Chicago (Chicago,
IL). HERG expressed in HEK-293 cells were obtained from Craig
January, University of Wisconsin, Madison, WI). U251 cells were
obtained from Pilar Martı´n Duque (Aragon Institute of Health
Sciences I+CS and ARAID, Zaragoza, Spain). Isolation of
PCAEC: Hearts were kindly provided by the local abattoir
(Matadero Mercazaragoza). Left anterior descending and poste-
rior descending coronary arteries (CA) were carefully dissected and
cleaned of connective tissue and fat. CA were cut open
longitudinally and incubated in trypsin/EDTA (0.25%/0,02%)
in PBS without Ca2+/Mg2+ (Biochrom KG) for 30 min. There-
after the luminal surface was carefully scrapped with a pipette tip
and cells were aspirated and transferred into culture dishes
containing cover slips. Cells were used for patch-clamp experi-
ments within 24 hrs.
Prior to electrophysiological studies, cells were trypsinized and
seeded on cover slips in a NaCl solution composed of (mM):
140 NaCl, 5 KCl, 1 MgSO4, 1 CaCl2, 10 glucose and 10 HEPES
(adjusted to pH 7.4 with NaOH). Cells were allowed to settle
down for 2–4 hrs and used for electrophysiological measurements
within 6 hrs.
Patch-clamp Electrophysiology
Whole-cell membrane currents were recorded using an EPC10-
USB patch-clamp amplifier (HEKA Electronics, Germany) using
voltage-ramps (2100 to 100 mV, 1 sec) followed by a single 0 mV
pulse for 1 sec (for quantifying the amplitude of K+-outward
currents) and analyzed with the PatchmasterTM software. Human
ERG currents were recorded with a pre-pulse to 280 mV (for
1 sec), followed by a depolarizing pulse to +30 mV (1 sec duration)
and a repolarizing pulse to 240 mV (500 msec duration) to
measure amplitudes of tail currents. Leak subtraction was not
performed during data acquisition, but ‘‘ohmic’’ leak of up to 6 nS
was subtracted at the time of data analysis if appropriate. For
activation of KCa currents, cell were dialyzed with a KCl-pipette
solution containing 1 mM [Ca2+]free (in mM): 140 KCl, 1 MgCl2,
2 EGTA, 1.71 CaCl2, and 5 HEPES (adjusted to pH 7.2 with
KOH). The pipette solution used for measuring Kv channels
contained 100 nM [Ca2+]free (2 mM EGTA, 0.7 mM CaCl2). The
composition of the NaCl bath solution was as stated above. For
single-channel recordings in inside-out patches from hKCa3.1-
overexpressing HEK293 cells, we used an Axopatch amplifier
(Axon Instruments) and post-filtered the data at 100 Hz. The bath
solution contained 0.5 mM [Ca2+]free (in mM): 140 KCl, 1 MgCl2,
2 EGTA, 1.48 CaCl2, and 5 HEPES (adjusted to pH 7.2 with
KOH). The bath solution stated above was used as pipette
solution. For blocking experiments, we used the selective KCa3.1
blocker TRAM-34 [5] (1 mM) and tested phenolic and poly-
phenolic compounds as stated in table 1 to evaluate potential
blocking efficiency. For calculation of EC50 values, data points
were fitted using the equation: y = A2+ (A1–A2)/(1+ (x/x0)‘p) or
the Boltzmann equation: y = A2+ (A1–A2)/(1+ exp((x-x0)/dx)),
depending on which equation gave the better fit. For further
activation or recovery of currents, the KCa3.1/KCa2.X activator
naphtho[1,2-d]thiazol-2-ylamine (SKA-31, 1 mM) was added to
the bath solution.
Cell Proliferation Assays
Cell proliferation was spectrophotometrically assessed as
described previously [28] with some modifications. Briefly, 3T3
fibroblasts (1500 cells/well) were seeded in 96-well plates (TPP.
Switzerland), cultured in DMEM containing 10% FCS (Lonza,
Switzerland) with 13b or vehicle (DMSO), and formalin-fixed at
days 0,1,2 and 3. To exclude the possibility that DMSO as vehicle
affected the cell viability per se, final DMSO concentrations were
the same for each concentration of 13b and the controls. Fixed
cells were stained for 5 minutes with 50 ul/well of 0.3% Janus B
Green dye (Acros Organics, Belgium) at room temperature with
constant stirring followed by a de-staining step with water. Dye
was eluted with 200 ul/well of 0.5 M HCl of hydrochloric acid
and top-read measurements of absorbance were performed in a
microplate reader (Sinergy HT, Biotek, USA) at 595 nm.
Myography on Porcine Coronary Arteries
Myography on porcine coronary artery rings was performed as
described in detail previously [29,30]. In brief, left anterior
descending arteries or posterior descending arteries were cut into
rings (3 mm long) and rings were mounted onto a isometric force
transducer (Pioden UF1, Graham Bell House, Canterbury, UK).
The organ bath contained a 5 ml Krebs buffer maintained at
37uC and gassed with 95% O2/5% CO2. The composition of the
Phenolic Inhibitors of KCa3/2 Channels
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Krebs buffer was as follows (in mM): NaCl 120, NaHCO3 24.5,
CaCl2 2.4, KCl 4.7, MgSO4 1.2, KH2PO4 1 and glucose 5.6,
pH 7.4. Each ring was passively stretched to an initial tension of
1 gr (10 mN). Changes in force were monitored and recorded on a
computer using a Mac Lab System/8e program (AD Instruments
Inc, Milford, Ma, USA), and digitalized at a sample rate of 0.5 sec.
To measure specifically endothelium-derived hyperpolarization-
mediated vasorelaxation (EDH), the NO-synthase blocker, Nv-
nitro-L-arginine (L-NNA, 300 mM), and the cyclooxygenase
blocker, indomethacin (10 mM), were added to the buffer.
Preparations were washed three times and were allowed to
equilibrate for 40 min. Within this period, the incubation medium
was renewed every 20 min. Compounds, alone or in combination,
13b (0.5 mM), SKA-31 (1 mM or 10 mM), 13b+SKA-31 (1 mM or
10 mM), or vehicle (DMSO) were tested as follows: First, rings
were pre-incubated with one compounds or the combination of
two for 5 min before the addition of serotonin (5-hydroxytrypta-
mine, 5-HT, 1 mM, 1st stimulation). Ten min later, bradykinin
(1 mM) was added for another 10 min, followed by washout (over
at least 10 min). This protocol was repeated (2nd stimulation).
Thereafter, we performed a 3rd round of pre-contraction and
vasorelaxation, but using the vasospasmic thromboxane analogue
U46619 (0.2 mM) as vasocontracting agent. At the end of the
experiments, rings were allowed to contract maximally in a KCl
(60 mM) buffer for 10 min followed by addition of the
compounds. Finally, sodium nitroprusside (10 mM) was added to
achieve maximal endothelium-independent vasorelaxation.
Stock solutions of 13b, SKA-31, and U46619 were made in
DMSO at the day of the experimentation and added to the Krebs
buffer in appropriate amounts to achieve the desired final
concentration. DMSO as the vehicle had no vasoactive effect
per se on the tissue. Other compounds were dissolved in Milli-Q
water.
For data analysis, we determined absolute increases in force to
5-HT, U46619, or 60 mM KCl. Bradykinin-induced relaxations
were determined as % change of pre-contraction to either
vasocontracting compound and relative to the fully relaxed state
(in the absence of the vasocontracting agent).
Compounds and Chemicals
The trivanillic esters, 13a, 13b, and 13c were kind gifts of Dr.
Delphine Lamoral-Theys, Laboratoire de Chimie Analytique,
Toxicologie et Chimie Physique Applique´e, Universite´ Libre de
Bruxelles (ULB), and Dr. Robert Kiss, Laboratoire de Toxicologie,
Institut de Pharmacie, ULB, Belgium, and were synthesized as
described previously [22,23]. Hydroxytyrosol was a kind gift of Dr.
Jesu´s Osada, Department of Biochemistry and Molecular and
Cellular Biology, Veterinary School, Health Research Institute of
Aragon, CIBEROBN, Zaragoza, Spain. The other compounds
were purchased from Sigma/Aldrich, Tocris, Alfa Aesar, or
Table 1. Inhibitory effects of natural and synthetic (poly)phenols, synthetic benzoic acids, and non-steroidal anti-inflammatory
drugs on KCa3.1 channels.
Compound % of control at
1 mM 10 mM 50 mM
Hydroxytyrosol ((2-hydroxyethyl)benzene-1,2-diol) 11769 108615 NT
Gallic acid (3,4,5-trihydroxybenzoic acid) NT 10166 NT
Vanillic Acid (4-hydroxy-3-methoxybenzoic acid) NT 78611 46612
Caffeic Acid ((E)-3-(3,4-dihydroxyphenyl)propenoic acid) 5966 22611 0.860.3
Ferulic Acid ((E)-3-(4-hydroxy-3-methoxyphenyl)propenoic acid) NT 8768 3264
Resveratrol (5-[(E)-2-(4-Hydroxyphenyl)vinyl]benzene-1,3-diol) NT 4461 1263
Caffeic acid phenethyl ester (2-phenylethyl (E)-3-(3,4-
dihydroxyphenyl)propenoate)
NT 9466 NT
1,2,3,4,6-pentagalloyl glucose ([(2S,3R,4S,5R,6R)-2,3,5-tris[(3,4,5-
trihydroxybenzoyl)oxy]-6-[(3,4,5-trihydroxybenzoyl)oxymethyl]oxan
-4-yl] 3,4,5-trihydroxybenzoate)
NT 10266 NT
2-acetyloxybenzoic acid (AspirinTM) NT 10865 10467
Mesalamine (5-amino-2-hydroxybenzoic acid) 7266 5367 4663
Mefenamic Acid (2-((2,3-dimethylphenyl)amino)benzoic acid) 11764 136628 NT
Niflumic Acid (2-((3-(trifluoromethyl)phenylamino) nicotinic acid) NT 10667 8164
Flufenamic Acid (2-(3-(trifluoromethyl)phenylamino) benzoic acid) 6564 1365 2.560.3
Modafinil (2-benzhydrylsulfinylacetamide) NT 3366 NT
Pirfenidone (methyl-1-phenylpyridin-2(1H)-one) NT 9865 99614
13a ([3,5-bis[(4-hydroxy-3-methoxy-benzoyl)oxymethyl]phenyl]methyl
4-hydroxy-3-methoxy-benzoate)
7866 NT NT
13b ([3,5-bis[(3-fluoro-4-hydroxy-benzoyl)oxymethyl]phenyl]methyl
3-fluoro-4-hydroxy-benzoate)
461 NT NT
13c ([3,5-bis[(3-chloro-4-hydroxy-benzoyl)oxymethyl]phenyl]methyl
3-chloro-4-hydroxy-benzoate)
61617 NT NT
TRAM-34 (1-[(2-chlorophenyl) (diphenyl)methyl]-1H-pyrazole) 161 NT NT
SKA-31 (naphtho[1,2-d] [1,3]thiazol-2-amine) 329676 (activation) NT NT
NT, not tested; data are given as mean 6 SEM, n $3.
doi:10.1371/journal.pone.0058614.t001
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derived from in-house synthesis (TRAM-34 [5], SKA-31 [27]).
Stock solutions (at 1 or 10 mM) of all compounds were prepared
with dimethylsulfoxide (DMSO). The final DMSO concentration
did not exceed 0.5% in single experiments testing one or more
compounds.
Statistics
Data are given as means 6 SEM. Data sets were compared
using one-way analysis of variance (ANOVA) and paired two-
tailed Student’s T test if appropriate and as indicated in the legend
text. P-values of ,0.05 were considered statistically significant.
Results
Identification of Natural Product, Caffeic Acid, the NSAID,
Flufenamic Acid, and the Synthetic Trivanillic Ester, 13b,
as Novel Small Molecule Inhibitors of KCa3.1 Channels
KCa3.1 channels in 3T3 fibroblasts [31] were activated by
infusion of 1 mM Ca2+ and showed KCa3.1-typical voltage-
independence and pronounced inward rectification at positive
membrane potential similar to previous reports on human and
rodent KCa3.1 [8,32]. Our electrophysiological screening of 20
phenolic, benzoic, and polyphenolic natural products on KCa3.1
channels in 3T3 fibroblasts (as summarized in Table 1, for
structures see Figure S1) revealed no (hydroxytyrosol, gallic acid,
caffeic acid phenethyl ester, 1,2,3,4,6-pentagalloyl glucose), weak
(vanillic acid, and ferulic acid, both with EC50s of .10 mM), or
moderate blockade (caffeic acid, EC50 1.360.2 mM, Figure 1A;
resveratrol, EC50 of <10 mM).
The synthetic benzoic acid derivatives, 3-fluoro-4-hydroxyben-
zoic acid and 4-amino-3-fluorobenzoic acid, had no appreciable
blocking effects (Table 1). In contrast, the established KCa3.1
blocker TRAM-34 [5] completely inhibited the KCa3.1 current at
1 mM as expected (Table 1 at bottom). The NSAIDs had variable
KCa3.1 blocking effects: Of the salicylates, 2-acetyloxybenzoic
acid (AspirinTM) had no effect while mesalamine had weak
blocking effects (EC50 2668 mM). Of the fenamates, flufenamic
acid was found to be a KCa3.1 inhibitor with moderate potency
(EC50 1.660.1 mM, Figure 1B) while niflumic acid and
mefenamic acid had no blocking effects at concentrations up to
50 mM. Modafinil, a synthetic biphenolic and analeptic drug that
have been previously shown to block KCa3.1 by increasing
cAMP-mediated phosphorylation [33], was found to be a weak
direct channel inhibitor (EC50 of .1 mM, Table 1) in the present
study. The 5-methyl-1-phenylpyridin-2-one, pirfenidone, a drug
approved for the treatment of idiopathic lung fibrosis [34], had no
effects on KCa3.1.
Of the diversely substituted trivanillic esters (Table 1), 13b had
considerable potency (Table 1 & Figure 2 A) as it blocked the
channel at concentrations in the low nanomolar range (EC50
1966 nM, Figure 2 A, on right). The Hill coefficient was close to
1, suggesting non-cooperative binding. The differently substituted
analogues 13c and 13c had only weak to moderate blocking
efficiency (Table 1) which could also be related to their even
poorer solubility (13a, LogP 7.4; 13c, LogP 8.8 vs. 13b LogP 6.5)
and possible precipitation in the physiological buffer used here.
13b also produced channel inhibition (461% of control, n = 5)
with a Ca2+ concentration as high as 100 mM at the cytosolic face
of the membrane and in the absence of the Ca2+-chelator EGTA,
ruling out that the blocking effects of 13b were caused by
interference (buffering) with cytosolic Ca2+ concentrations and
Ca2+-sensitivity of the channel to higher Ca2+ concentrations
(Figure S2).
Reversibility of the Channel Blockade by the Positive
Gating Modulator SKA-31
The channel blockade caused by submicromolar concentrations
of 13b was reversed by 1 mM of the positive gating modulator of
KCa3.1/KCa2 channels, SKA-31 [27] (see Table 1 for channel
activation and Figure 2B, panels on left for reversibility of
blockade). However, SKA-31 was substantially less effective at
rescuing the current blocked by 1 mM 13b (Figure 2B, upper panel
on right). The calculated EC50 of 13b to suppress the SKA-31-
induced current was 1616121 nM. When the less potent
inhibitors caffeic acid and flufenamic acid were used, 1 mM
SKA-31 was able to recover the KCa3.1 current blocked by
10 mM flufenamic acid (661% of control, n = 3) to half the level of
the initial current (53620% of control). The current blocked by
10 mM caffeic acid (28610% of control, n = 4) was likewise
recovered by 1 mM SKA-31 (59611% of control) but similar to
flufenamic acid the current amplitude did not reach its initial
amplitude. These dose-dependent antagonizing effects of 13b (and
the weaker ones of flufenamic acid and caffeic acid) suggested an
interaction of the inhibitor and the activator with the channel
protein at the same or nearby binding site(s) with a higher affinity
of 13b than for SKA-31, but we cannot rule out allosteric
antagonism.
Single Channel Experiments
In a series of inside-out experiments on the cloned human
KCa3.1 channel overexpressed in HEK293 cells (Figure 2C), we
tested whether the blocking effect of 13b was indeed due to a
direct effect on the channel or possibly mediated through
alteration of enzymatic channel regulation [35,36,37] or elicited
by potential metabolites of 13b. These experiments revealed that
13b blocked the channels in the ‘‘isolated’’ inside-out patch with a
similar EC50 of 1463 nM and a Hill coefficient close to 1
(Figure 2 C, lower panel on right). Similar to the whole-cell
experiments, SKA,-31 was also effective in antagonizing the
blocking effects of nanomolar concentrations of 13b (Figure 2 C,
lower panel on left) but could not recover currents blocked by
1 mM of 13b (Figure 2 C, upper panel on right). Again similar to
the whole-cell experiments, the other derivatives, 13a and 13c, did
not block the ‘‘isolated’’ channel in inside-out patches. TRAM-34
at 1 mM produced a complete block of channel currents in the
absence of SKA-31 and of the currents recovered by SKA-31
(Figure 2C, lower panel on right and left).
Selectivity of 13b
We next tested whether 13b would also affect the related KCa2
channels and indeed found that 13b blocked the human KCa2.3
in COS7 cells, although with a substantially lower EC50 of
3606173 pM (Figure 3A, upper panels). Like for KCa3.1, the Hill
coefficient was close to 1, suggesting again non-cooperative
binding of 13b. The rescue of the current by SKA-31 was similar
to that observed in KCa3.1-expressing cells (Figure 3B).
As expected, the widely used selective KCa2 channel blocker
UCL1684 [38], that binds to the outer vestibule of the channel,
fully blocked (261% of control at 100 nM, n = 4) the hKCa2.3
current pre-activated by 1 mM SKA-31 (11576485% of control,
n = 4; Figure S3). In contrast to KCa3.1 channels, caffeic acid,
flufenamic acid, 13a, and 13c had no blocking effects on
KCa2.3 at micromolar concentrations (Table S1). Like for
KCa3.1, we confirmed blocking efficacy of 13b in inside-out
single channel experiments and determined a slightly lower
EC50 of 2416129 pM and a Hill coefficient close to 1
(Figure 3 C). SKA-31 recovered the current blocked by 1 nM
Phenolic Inhibitors of KCa3/2 Channels
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13b (Figure 3 C, traces on left, summary of data and dose-
response curve on right).
In contrast to KCa2 and KCa3.1, the phylogenetically
distantly related large-conductance voltage-gated and non-
calmodulin-regulated KCa1.1 in human U251 glioblastoma
cells was not blocked by 13b (Table S1) while flufenamic acid at
10 mM was found to potentiate KCa1.1 by 2.7-fold similar to a
previous report [39] and caffeic acid at 10 mM had no blocking
or activating effects (Table S1). The cloned human voltage-
gated K+ channel, hKv1.2, showed moderate sensitivity to 13b
at 100 nM (19% inhibition) and was half-maximal block at
0.5 mM (EC50 0.5560.01 mM, Figure S4 and Table S1),
suggesting that 13b loses selectivity for KCa3.1/KCa2 channels
in the micromolar range. Flufenamic acid and caffeic acid did
not block hKv1.2 at 10 and 50 mM (Table S1). The other
trivanillic ester 13a blocked hKv1.2 currents by 50% at 1 mM
while 13c at 1 mM had no effect (Table S1). Cloned hKv1.3
channels were not inhibited by 13b at a concentration of 10 mM
(Table S1). Also, cloned voltage-gated hERG channels were not
blocked by either 13b or caffeic acid, while flufenamic acid
caused a slight potentiation as also described previously [40]
(Table S1). A native inward-rectifying K+ current (Kir) in U251
glioblastoma cells was not blocked by 13b at 1 mM (9862% of
control at 2100 mV, n = 5), suggesting no blocking effects on
this structurally different class of K+ channels.
Cell Proliferation Assay
High functional expression of KCa3.1 has been proposed to
promote cell proliferation in various tissues [21] and cell lines
including fibroblasts [13,14] and pharmacological inhibition of the
channel has been shown to reduce cell proliferation
[5,11,14,19,20]. To demonstrated utility of caffeic acid and 13b
as KCa3.1 inhibitor in the present study, we evaluated the effects
of the compounds on the proliferation of 3T3 fibroblast by a
colorimetric assay. As shown in figure 4, cells proliferated in a
time-dependent fashion regardless of the treatment. However,
increasing doses of caffeic acid significantly slowed down the
proliferation of 3T3 cells in a dose-dependent manner compared
to vehicle-treated controls (227% and 256% at 25 mM and
50 mM, respectively; Fig. 4A). Likewise, 13b inhibited cell
proliferation at day 3 by 20%. However, we did not observe
differences between the two doses (0.5 and 2 mM; 223 and –20%;
Fig. 4B).
Blockade of Native Porcine Endothelial and Vasoactive
Properties of 13b
KCa3.1 and KCa2.3 are key players in the endothelium-
dependent control of arterial tone by producing endothelial
hyperpolarization and thereby endothelium-dependent vasorelax-
ation resistant to inhibition of NO- and prostacyclin synthesis [21].
As a further proof of functionality and utility of 13b as a potent
KCa3.1/KCa2.3 inhibitor in a more complex physiological
Figure 1. Pharmacological modulation of KCa3.1 channels by natural phenols and NSID. Original recordings of KCa3.1 whole-cell currents
in 3T3 fibroblasts are shown. Currents were activated by infusion of 1 mM Ca2+free via the patch-pipette and exhibited voltage-independence and
inward-rectification typical for KCa3.1. A) On left: Complete inhibition of KCa3.1 channels by caffeic acid. On right: Weak inhibition by vanillic acid. B)
On left: Complete inhibition of KCa3.1 channels by flufenamic acid. On right: The structurally similar niflumic acid had no blocking activity.
doi:10.1371/journal.pone.0058614.g001
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Figure 2. Inhibition of KCa3.1 channels by polyphenolic trivanillic ester, 13b. Original recordings of fibroblast KCa3.1 currents pre-activated
by infusion of 1 mM Ca2+free via the patch pipette. A) On left: Complete inhibition of KCa3.1 currents by 1 mM 13b. On right: Dose-response
relationship for 13b. Fitting data points (representing means 6 SEM, n = 4–9 each) gave an EC50 of 19 nM. B) Upper panel on left: Reversibility of
KCa3.1 blockade with 10 nM 13b (applied 1st) by 1 mM SKA-31 (2nd). Lower panel on left: Moderate reversibility of KCa3.1 blockade with 100 nM 13b
(applied 1st) by 1 mM SKA-31 (2nd). Upper panel on right: Poor reversibility of KCa3.1 blockade with 1 mM 13b (applied 1st) by 1 mM SKA-31 (2nd).
Lower panel on right: Summary of data for reversibility. Data points are given as mean6 SEM (n = 4–8 each). C) Inhibition of hKCa3.1 currents by 13b
in inside-out patches from hKCa3.1 overexpressing HEK293 cells. The hKCa3.1 currents were activated by excising the patch and exposure of the
cytosolic face of the channel to the high K+ and 0.5 mM Ca2+free containing bath solution. The pipette solution was contained physiological amounts
of Na+ and K+. Upper panel on left: Inhibition of hKCa3.1 by 1 mM 13b. Lower panel on left: Half inhibition of KCa3.1 by 10 nM 13b (1st), full recovery
after addition of 1 mM SKA-31 (2nd), and full blockade of the recovered current by 1 mM TRAM-34 (3rd). Upper panel on right: SKA-31 was not very
effective at reversing the blockade caused by 1 mM 13b. Lower panel on right: Dose-response curves for the 13b blockade in inside-out patches (filled
squares, n = 3–4) and recovery by 1 mM SKA-31 (filled circles, n = 3–4 each). Fitting of the data points (filled squares) gave an EC50 of 14 nM. TRAM-34
produced complete channel blockade of the recovered currents (open triangles, n = 2) while 1 mM 13c (open squares, n = 2) and 1 mM 13a (filled
boxes, n = 2) had no or minor blocking effects.
doi:10.1371/journal.pone.0058614.g002
Figure 3. Inhibition of closely related hKCa2.3 by 13b. In fast whole-cell experiments, cloned hKCa2.3 were activated by infusion of 1 mM
Ca2+free via the patch-pipette. A) Panel on left: 13b at 100 pM inhibited KCa2.3 currents by approx. half. Panel on right: Dose-response relationship.
Fitting of data points (representing means 6 SEM, n = 3–9 each) gave an EC50 of 360 pM. B) Reversibility of complete channel blockade (at 100 nM
13b) by 1 mM SKA-31. C) Inhibition of hKCa2.3 by 13b in inside-out single-channel experiments. On left: original traces of inhibition by 100 pM 13b
and SKA-31-induced recovery of currents blocked by 1 nM 13b. Full inhibition of the SKA-31-induced currents by UCL1684. On right: summary of data
and dose-response curve. Data are given as means 6 SEM, n = 2–5 each.
doi:10.1371/journal.pone.0058614.g003
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setting, we determined sensitivity of KCa3.1 and KCa2.3
functions to 13b in native porcine coronary artery endothelial
cells and tested by isometric myography on porcine coronary
artery rings whether 13b altered relaxation to bradykinin alone
and to bradykinin in combination with SKA-31. In addition, we
tested whether 13b modified contractions to serotonin (5-HT) and
the vasospasmic thromboxane analogue U46619. For this, we
chose a concentration of 0.5 mM of 13b which was more than 10-
fold above the EC50 for KCa3.1 and KCa2.3 channels but had
little blocking effects on hKv1.2 channels possibly expressed in the
smooth muscle of these coronary arteries.
Using whole-cell patch-clamp experiments we first confirmed
that PCAEC like other species expressed mixed KCa3.1 and
KCa2.3 currents (Figure 5). These currents with a mean amplitude
of 3068 pA/pF (n = 9) were almost completely blocked by 1 mM
13b (1467% of control, n = 3). The KCa3.1 blocker TRAM-34
blocked half of the total KCa current at 1 mM (5864% of control,
n = 4) and the remaining current mediated by KCa2.3 was
blocked by 1 mM 13b (964% of control, n = 4). A current
potentiated by 1 mM SKA-31 was almost fully blocked by 1 mM
13b. Flufenamic acid at 10 mM blocked the mixed KCa3.1/
KCa2.3 to 2563% of control (n = 2). Flufenamic acid and caffeic
acid, both at 50 mM (n = 1) blocked the currents almost completely
to 3 and 6% of control, respectively.
Myography data (means, SEM, and n, P values from statistical
calculations) were summarized in the tables 2, 3, 4 and showed
that 13b at 0.5 mM did not produce contractions in its own right or
interfered with endothelium-independent contractions to 60 mM
K+ or with the endothelium-independent relaxations to the NO-
donor sodium nitroprusside (Tables S2 and S3). Likewise, the
KCa3.1/KCa2.3 activator SKA-31 at 1 or 10 mM did not
produce contractions or relaxations in its own right or interfered
with contractions to 60 mM K+ or relaxations to sodium
nitroprusside (Tables S2 and S3). In contrast, 0.5 mM 13b
augmented the amplitude of contraction induced by 1 mM 5-HT
by +74% when compared to vehicle (DMSO)-treated rings
(P,0.01; Table 2). SKA-31 at 1 or 10 mM as well as SKA-31 in
combination with 0.5 mM 13b did not modify contraction to 5-
HT, with the only exception of reduced contractions in the
presence of 10 mM SKA-31 plus 0.5 mM 13b (258%, P,0.01 vs.
vehicle; Table 2). After wash out (20 min), a repetition of the
protocol gave similar results (2nd stimulation in Table 2), i.e. a
stronger contraction with 13b (+90%, P,0.01 vs. vehicle), and
weaker contractions in the presence of 10 mM SKA-31 (244%,
P,0.05 vs. vehicle) or 10 mM SKA-31 plus 0.5 mM 13b (244%,
P,0.05 vs. vehicle).
As shown in table 3, the vasospasmic thromboxane analogue
U46619 (0.2 mM) produced substantially stronger contractions
(amplitude of force: U46619, 2.2 g vs. 5-HT, 0.35 g). These
contractions were further enhanced (+29%) by 13b (P,0.05 vs.
vehicle). SKA-31 at 1 mM and 10 mM did not significantly modify
these contractions but prevented the stronger contractions caused
by 13b (25%, n.s., and 214%, n.s. vs. vehicle, respectively).
As shown in table 4, bradykinin at 1 mM produced a 30%
relaxation of 5-HT-precontracted and vehicle-treated rings (1st 5-
HT contraction). This relaxation was not significantly reduced by
13b (227%, n.s. vs. vehicle). In contrast, SKA-31 at 1 and 10 mM
augmented the relaxation (+110% and +52%, respectively;
P,0.01 vs. vehicle) and 13b at 0.5 mM was efficient to largely
prevent the potentiation of the bradykinin response caused by
1 mM SKA-31 (+23%, n.s. vs. vehicle) but not by 10 mM (+123%;
P,0.001 vs. vehicle). This finding was in line with the notion that
high concentrations of SKA-31 antagonized the 13b blocking
effects on KCa3.1 and KCa2.3 channels as observed in the
electrophysiological experiments.
In experiments on U46619-precontracted rings, bradykinin
failed to relax these strongly contracted rings, rather the rings
continued contracting (+10% contraction in the presence of the
vehicle). The rings also continued contracting in the presence of
0.5 mM 13b albeit to some lesser degree (+1% contraction;
P,0.01 vs. vehicle). In contrast, combined stimulation with
bradykinin and SKA-31 at 1 and 10 mM elicited small but
appreciably relaxations (5% and 10% relaxation; both P,0.01 vs.
vehicle) of these U46619-precontracted rings. 13b prevented by
trend the relaxation produced by the combination of bradykinin
plus 1 mM SKA-31 (2% relaxation, n.s. vs. bradykinin plus 1 mM
SKA-31 alone), but not the relaxation produced by bradykinin
plus 10 mM SKA-31 (8% relaxation, n.s.). The latter findings were
again in line with the antagonizing effects of high concentrations of
SKA-31 on 13b-induced channel inhibition. Together, the
myography revealed that 13b was functionally active as a
KCa3.1/KCa2.3 inhibitor in an artery by promoting vasocon-
straction and counteracting endothelium-dependent vasorelax-
ation caused by pharmacological KCa3.1/KCa2.3 activation.
Discussion
The main outcome of our study was: 1) the natural phenol
caffeic acid and the NSAID, flufenamic acid, were found to be
moderately potent KCa3.1 inhibitors with EC50s in the lower
micromolar range. 2) The synthetic tri-fluoro trivanillic ester, 13b,
was identified as a potent KCa3.1 inhibitor with a low EC50 of
19 nM. Moreover, 13b acted as a novel type of negative gating
modulator of KCa3.1 channels as evidenced by the antagonizing
capabilities of the positive gating modulator SKA-31. 3) 13b
blocked closely related KCa2.3 channels with even higher potency
(EC50 360 pM). 4) 13b was found to be non-toxic in cultured 3T3
fibroblasts and reduced proliferation at submicromolar concen-
tration by 20%. 5) 13b blocked native KCa2.3/KCa3.1 channels
in porcine endothelium and augmented contractions of porcine
coronary arteries induced by 5-HT and or the vasospasmic
Figure 4. Inhibition of proliferation of 3T3 fibroblasts. 3T3-L1
fibroblasts were treated with increasing doses of the DMSO-solubilized
phenolic compounds caffeic acid (A) and 13b (B) for 3 days. Experiments
were repeated three times and data (absorption, ABS) were expressed
as the means 6 SEM of 8 replicates for each condition. Student’s T-test
was used for statistical comparison of data sets at any given time point.
For caffeic acid: *p,0.01 vs. control (vehicle), #p,0.001 vs. 25 mM;
"p,0.05 for 13b at 0.5 and 2 mM vs. control.
doi:10.1371/journal.pone.0058614.g004
Phenolic Inhibitors of KCa3/2 Channels
PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e58614
thromboxane analogue U46619. 13b reduced the endothelium-
dependent relaxation to combined stimulation with bradykinin
and SKA-31. Together these findings identify 13b as new and
potent pan-inhibitor of KCa2/KCa3.1 channels.
Natural phenolic or benzoic phytochemicals, although known to
exert multiple pharmacological effects, have not been previously
described to block KCa3.1/KCa2.3 channels. Our screening
identified caffeic acid and resveratrol as the first natural phenolic
phytochemicals with a remarkable KCa3.1-blocking efficacy as
indicated by EC50s in the lower micromolar range (1–10 mM).
Concerning the benzoic NSAIDs, flufenamic acid has previously
been shown to block calcium-activated chloride channels as well as
non-selective cation channels, with reported EC50s of approx. 30
and 5 mM, while an inhibitory effect on KCa3.1 has not been
described so far. Here, we found that flufenamic acid was a
moderately potent KCa3.1 inhibitor with an EC50 of 1.6 mM.
From the pharmacological perspective, it could thus be tempting
to speculate that inhibitory actions of either caffeic acid,
resveratrol, or flufenamic acid on KCa3.1 channels were part of
the mechanisms by which caffeic acid and flufenamic acid
produced anti-inflammatory effects and altered carcinogenesis as
described previously [41,42]. Notwithstanding, the potencies of
caffeic acid, resveratrol, and flufenamic acid as KCa3.1-inhibitors
Figure 5. Inhibition of KCa channels by 13b and TRAM-34 in freshly isolated porcine coronary artery endothelial cells. Representative
whole-cell current recordings are shown. Upper panel on left: 13b-blockade of KCa currents (activated by infusion of 1 mM Ca2+free via the patch-
pipette; cells, n = 3). Upper panel on right: Blockade of KCa3.1 current by 1 mM TRAM-34 and blockade of the residual current (KCa2.3) by 13b (n = 4).
Lower panel on left: Blockade of SKA-31-activated currents by 1 mM 13b (n = 1).
doi:10.1371/journal.pone.0058614.g005
Table 2. 13b and SKA-31 modulate 5-HT-induced
contractions in porcine coronary artery.
Compound(s) 1
st stimulation 2nd stimulation
n Dg P vs. Ve n Dg P vs. Ve
Vehicle (Ve) 7 0.460.1 7 0.460.1
13b 0.5 mM 8 0.760.1 ,0.5 7 0.760.1 ,0.01
SKA-31 1 mM 4 0.460.1 n.s. 4 0.560.1 n.s.
SKA-31 10 mM 5 0.460.1 n.s. 5 0.2360.02 ,0.5
13b 0.5 mM+SKA-31 1 mM 4 0.460.1 n.s. 4 0.660.1 n.s.
13b 0.5 mM+SKA-31 10 mM 5 0.1660.02 ,0.01 5 0.2260.03 ,0.5
Data are given as mean 6 SEM; n.s. not significant.
doi:10.1371/journal.pone.0058614.t002
Table 3. 13b and SKA-31 modulate U46619-induced
contractions in porcine coronary artery.
Compound(s) n Dg P vs. Ve
Vehicle (Ve) 8 2.260.2
13b 0.5 mM 7 2.860.2 ,0.5
SKA-31 1 mM 4 1.960.5 n.s.
SKA-31 10 mM 4 1.760.2 n.s.
13b 0.5 mM+SKA-31 1 mM 4 2.360.4 n.s.
13b 0.5 mM+SKA-31 10 mM 4 1.960.2 n.s.
Data are given as mean 6 SEM; n.s. not significant.
doi:10.1371/journal.pone.0058614.t003
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were moderate, but still may further advocate caffeic acid and
resveratrol -as natural food additive-, or caffeic acid containing
vegetable oils, like extra-virgin olive oil and argan oil, and the
classical NSAID flufenamic acid for e.g. adjuvant immune
suppressive or cytostatic treatments or for topical applications for
inflammatory skin diseases.
The main outcome of our small scale screening study was the
identification of the 3-fluoro trivanillic acid ester 13b as a
nanomolar inhibitor of KCa3.1 channels, and, intriguingly,
picomolar inhibitor of KCa2.3 channels. At present, this makes
13b the most potent known small molecule inhibitor of KCa2.3
whereas its potency on KCa3.1 was similar to the known and
structurally unrelated blockers ICA-17043 (Senicapoc), TRAM-
34, and NS6180 [43]. Interestingly, the meta-substitution of the
fluoride atom of the phenol moiety by a methoxy group as in 13a
or by a chloride atom as in 13c, virtually abolished efficacy of these
analogues, suggesting that the fluoride is crucial for interaction
with the channels.
While 13b did not discriminate very well between small-
conductance KCa channels (KCa2) and the intermediate-
conductance channel (KCa3.1), the distantly related voltage-gated
large-conductance KCa channel KCa1.1 with another type of
calcium-sensitivity (non-calmodulin-conferred) was not blocked by
13b. Concerning voltage-gated K+ channels, 13b had only
moderate but still appreciable blocking effects on hKv1.2 channels
(EC50 0.55 mM) while it did not block hKv1.3 channels and
hERG channels. This selectivity profile indicated substantial
selectivity for KCa2/KCa3.1 channels over voltage-gated K+
channels.
Regarding the potential binding site/interaction site of 13b, we
suggest here that it might be located in the vicinity of the site at
which the positive gating-modulator SKA-31 is acting because
SKA-31 was capable to functionally antagonize 13b in our patch-
clamp experiments. However, there is of course also the possibility
that the antagonism is not direct but instead allosteric as between
the negative gating modulator NS8583 and the positive gating
modulator NS309 on KCa2.3 channels [44]. Unlike 13b, the
classical KCa3.1 blocker TRAM-34, which is binding to a putative
site below the selectivity filter of KCa3.1 [45] did not interfere with
the positive gating modulation of SKA-31, but fully blocked
currents activated by micromolar concentration of SKA-31 as well
as 13b-pre-blocked/SKA-31-recovered currents. These different
blocking properties of 13b and of TRAM-34 and the lack of
interaction of both TRAM-34 and 13b argued in favor of a
different binding site and molecular mechanism by which 13b
causes channel blockade. Together, these data suggested that 13b
could represent the first example of a new type of negative gating
modulator for KCa3.1 channels. Interestingly, another negative
gating modulator, NS8593 has recently been described for KCa2
channels [44], which interacts with the inner pore of KCa2
channels close to the internal gate at a same site at which TRAM-
34 causes inhibition of KCa3.1. However, based on the much
larger molecular size of 13b we believe it rather unlikely that 13b
acts as a negative gating modulator by entering the narrow inner
pore of KCa2/3 channels in the same way as TRAM-34 and
NS8593. Another fact that clearly distinguishes the fluoro-
trivanillic ester 13b from NS8593 is its lack of calcium-
dependence. While NS8593 becomes less potent at higher internal
Ca2+ concentrations, 13b can still fully block KCa2/3 channels
even in the presence of 100 mM of free internal Ca2+.
Regarding the binding sites of the positive gating modulators of
KCa3.1 and KCa2 channels, the positive gating modulators EBIO
and NS309 (structurally related to SKA-31) were recently shown
to bind in a pocket within the space between calmodulin and the
C-terminal calmodulin-binding domain (CAMBD) as concluded
from docking experiments using the recently solved structure of a
co-crystal of CAM and the C-terminus of KCa2.2 into which
EBIO had been soacked [46]. Assuming that SKA-31 uses the
same binding pocket in KCa3.1 and KCa2.3 channels, we suggest
that 13b might be binding in or near the same pocket where it
could be displaced by SKA-31. However, we can of course not
completely exclude allosteric effects mediated through interactions
of 13b and SKA-31 with non-overlapping sites.
The second major aim of the study was to demonstrate the
utility of this new and highly efficient inhibitor for studying cellular
and physiological processes to which KCa3.1 and/or KCa2.3
channels have been proposed to contribute.
Treatment of 3T3 fibroblasts with 13b at a submicromolar
concentration of 0.5 mM and at 2 mM moderately reduced cell
proliferation (-20%), similar to that what had been previously
observed in another murine renal fibroblast cell line using TRAM-
34 as a KCa3.1 blocker [14]. Interestingly, caffeic acid had even
more potent antiproliferative effects on 3T3 fibroblast although
these were achieved at 50 and 100 times higher (micromolar)
concentrations.
In the vascular endothelium, KCa3.1 and KCa2.3 channels are
key players in the initiation of endothelium-derived hyperpolar-
ization(EDH)-mediated arterial dilations [21]. Moreover, KCa3.1
activation has been suggested to be more important for EDH
dilation following the stimulation of G-protein-coupled receptors
while KCa2.3 channel function was reported to support the tonic
vasodilating influence of the endothelium and shear stress-induced
EDH dilation, thus assigning distinct functional roles to the
channels for different endothelial vasodilator functions [47].
Table 4. Modulation of bradykinin-induced relaxation in porcine coronary artery by 13b and SKA-31.
Compound(s) 5-HT-precontraction U46619-precontraction
n % relaxation P vs. Ve n % relaxation P vs. Ve
Vehicle (Ve) 6 3165 7 21162
13b 0.5 mM 7 2462 n.s. 7 2161 ,0.001
SKA-31 1 mM 4 6566 ,0.01 4 561 ,0.001
SKA-31 10 mM 5 4768 ,0.05 5 1062 ,0.001
13b 0.5 mM+SKA-31 1 mM 3 3868 n.s. 4 261 ,0.001
13b 0.5 mM+SKA-31 10 mM 5 6964 ,0.001 5 862 ,0.001
Data are given as mean 6 SEM; n.s. not significant.
doi:10.1371/journal.pone.0058614.t004
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Considering 13b as an endothelial KCa3.1/KCa2.3 inhibitor, we
expected that 13b would be vasoactive by influencing these
endothelial functions. Indeed, our myography on porcine coro-
nary arteries revealed that 13b augmented the contractile
responses to 5-HT and to the vasospamic U46619 at a
submicromolar concentration (0.5 mM). From the physiological
perspective, these results suggested that the inhibition of endothe-
lial KCa3.1 and KCa2.3 in porcine coronary arteries abolished a
tonic (KCa2.3) and/or agonist-induced (KCa3.1) endothelium-
derived negative feedback on 5-HT or U46619 induced contrac-
tions.
In keeping with the notion that SKA-31 antagonized 13b
actions on the channels in patch-clamp experiments, we also
expected SKA-31 antagonism of the pro-contractile effects of 13b.
In fact, SKA-31 at the higher concentration of 10 mM fully
antagonized the pro-contractile effects of 13b on 5-HT-induced
contractions and even reduced the contractions elicited by 5-HT
alone. In addition, SKA-31 also antagonized the pro-contractile
effects of 13b on the strong contractions to U46619. Thus, these
findings confirmed our idea that SKA-31 was capable of reversing
the 13b-blockade of the channels and of promoting vasorelaxation
in the presence of a vasocontracting neurotransmitter or a
vasospamic agent.
Concerning endothelium-derived hyperpolarization-induced
relaxation caused by G-protein-coupled receptor stimulation (here
of bradykinin receptors), 13b had no significant effect on
bradykinin–induced relaxation of 5-HT pre-contracted vessels,
suggesting that both channels were not required for this type of
relaxation in porcine coronary arteries. In contrast, SKA-31 as an
endothelial KCa3.1/KCa2.3 activator greatly augmented the
relaxation caused by bradykinin. 13b prevented this SKA-31-
mediated potentiation of the bradykinin-induced relaxation at
1 mM SKA-31, indicating that 13b was capable to antagonize the
vasorelaxation to combined stimulation with bradykinin by
blocking the -under these conditions substantially active- endo-
thelial KCa3.1/KCa2.3 channels. Because of the strong antago-
nizing effects of high doses of SKA-31 on the 13b blockade, 13b
was predictably unable to reduce the larger bradykinin-induced
relaxations at the higher 10 mM concentration of SKA-31.
Concerning the U46619-precontracted vessels, bradykinin effec-
tively produced relaxations of small amplitude only in the presence
of SKA-31, suggesting that the endothelium in the absence of NO
and prostacyclin synthesis was hardly able to counteract the strong
tone produced by the vasospasmic U46619. 13b antagonized these
weak relaxation responses only by trend at the lower concentration
of SKA-31 while it had clearly no effect at the higher
concentrations of SKA-31, thus supporting the idea that 13b did
not modulate bradykinin responses but antagonizes effects caused
by SKA-31.
13b did not alter contractions in response to high K+
concentrations and the relaxation to the NO donor sodium nitro
prusside indicating that the compound did not interfere with
calcium-dependent contractility of the smooth muscle and
endothelium-independent relaxation and has therefore no gross
unspecific effects on smooth muscle functions.
In sum, the myography experiments revealed that 13b was a
vasoactive KCa3.1/KCa2.3 inhibitor and acted by augmenting
vasocontraction to agonists and impaired EDH-vasorelaxation to
combined bradykinin stimulation and pharmacological opening of
endothelial KCa3.1/KCa2.3.
KCa3.1/KCa2.3 channels are key players in the proliferation of
some cell types and cancer cell lines as well as in endothelial
function [15,21]. As a structurally novel, potent, and pan-
KCa3.1/KCa2 channel active inhibitor 13b constitutes a new
tool compound to further study the physiological and pathophys-
iological roles of these channels and might also have therapeutic
utility in disease states, like chronic inflammation and autoimmune
disease, atherosclerosis, fibrosis, cancer, and hypotension to which
KCa3.1/KCa2 channel up-regulation or activation contribute.
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